# A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

> **NCT05025085** · PHASE1 · COMPLETED · sponsor: **Agenus Inc.** · enrollment: 25 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** AGEN1777
- **DRUG:** a PD-1 inhibitor

## Key facts

- **NCT ID:** NCT05025085
- **Lead sponsor:** Agenus Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-04
- **Primary completion:** 2023-07-11
- **Final completion:** 2024-04-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05025085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05025085, "A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05025085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*